65,437 trials
Head and Neck Cancer · Metastatic Squamous Neck Cancer With Occult Primary Squamous Cell Carcinoma · Recurrent Metastatic Squamous Neck Cancer With Occult Primary
Primary: Overall Survival — 10.7 Months
Pain Management
Primary: The Sum of Pain Intensity Differences (SPID) Through 48 Hours Post First Dose — -122.8; -110.9; -97.8 score on a scale — p=<.005
Persistent Pulmonary Hypertension of the Newborn
Primary: CD16/41 — 1.90; 1.13 percent change
Systemic Lupus Erythematosus
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs) in Part 1 Treatment Phase — 5; 7; 7; 8 Participants
Heart Failure · Heart-assist Devices
Primary: Reach of Intervention — 107; 64 Participants
Immunologic Activity Alteration
Primary: Cytokines Profile in Cord Blood Plasma — 1.6; 21.81; 165; 14 pg/ml
Schizophrenia
Primary: Social Attention: Social Engagement Latency (SEL) — 21618 msec
Hemorrhagic Shock
Primary: Survival — 16; 21 participants — p=.252
Heart Failure and Reduced Ejection Fraction
Primary: Change From Baseline in Aortic Characteristic Impedance at Week 12 — -0.7; -2.9 dyne x sec/cm5 — p=0.7827
HIV Infections
Primary: Period 1: Area Under the Plasma Concentration-time Curve From Time 0 to the End of the Dosing (AUC[0 to Tau]) of Dolutegravir for Dolutegravir Arm — 64627.8 Hours*…
Laparoscopy
Primary: Investigators Assessment of Tachosil — 1.91; 1.86 score on a scale
Pain, Intractable · Pain, Back
Primary: Change in Visual Analog Scale Pain (VAS) Scores Between Baseline and Trial Stimulation — -46.28 units on a scale
Phase I Study in Healthy Volunteers to Evaluate ECG Effect
Primary: Change-from-baseline QTcF (ΔQTcF) — 2.8; 9.2; 8.5; 1.1 msec
Fractures, Bone · Nausea and Vomiting, Postoperative · Pruritus
Primary: Quality of Recovery — 184; 187; 185 Score on a scale
Menopause
Primary: Vaginal Cytokines at Baseline — 2.73; 3.19; 0.12; 0.04 pg/ug protein